Dogwood Therapeutics, Inc.
DWTX Nasdaq· Pharmaceutical Preparations
Last close · Oct 23, 2026
$1.12
KIRA · Stoqly’s AI analyst, in plain words
- Dogwood Therapeutics, Inc. lost $34.3M in fiscal 2025.
Market cap
$38.2M
P/E
0.4x
Revenue
—
Net income
−$34.3M
Free cash flow
—
Operating margin
—
Dogwood Therapeutics, Inc. in 30 seconds · fiscal 2025
Does it make a profit?
−$34.3M
No. It lost money last year.
How is the share priced?
0.4x
One share costs 0.4 times its yearly profit per share.
What Dogwood Therapeutics, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 18, 2026
- Legal name
- Dogwood Therapeutics, Inc.
- CIK
- 0001818844
Dogwood Therapeutics, Inc. · DWTX
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $0.0M | $0.1M | $0.2M | — | — |
| Revenue growth | — | 1,084.2% | 123.6% | — | — |
| Net interest income | $0.0M | $0.1M | $0.2M | — | — |
| Operating margin | −274,401.8% | −18,244.9% | −3,609.6% | — | — |
| Net income | −$16.0M | −$12.2M | −$5.3M | −$12.3M | −$34.3M |
| Net margin | −280,005.3% | −18,144.9% | −3,509.6% | — | — |
| Diluted EPS | −$1.92 | −$1.11 | −$7.05 | −$12.52 | −$7.13 |
| Cash | |||||
| Cash from operations | −$15.7M | −$11.5M | −$4.9M | −$8.8M | −$15.6M |
| Share count change | 69.1% | 32.9% | −93.2% | 36.8% | 384.3% |
| Debt and strength | |||||
| Cash and short-term investments | $14.0M | $7.0M | $3.3M | $14.8M | $6.5M |
| Shareholders' equity | $14.5M | $7.3M | $3.8M | −$10.1M | $74.9M |
| Current ratio | 12.4x | 8.0x | 11.6x | 5.2x | 2.8x |
| Returns and quality | |||||
| Return on equity | −71.8% | −112.2% | −95.1% | — | −105.8% |
| Return on tangible equity | −110.1% | −167.2% | −139.1% | — | — |
| Piotroski F-score | 2 | 2 | 5 | — | — |
| Altman Z'' | 2.2 | −18.7 | −39.8 | −2.8 | −0.5 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Dogwood Therapeutics, Inc. · DWTX
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $1.12 a share, the company is worth $38.2M: 0.4 times its earnings of the last four quarters.
Source: SEC EDGAR XBRL filings (CIK 0001818844). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.